-
2010
8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...
-
Meet us
The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...
2006
Hervé, J.C. and Dhein, S.:
Pharmacology of cardiovascular gap junctions
Advances in cardiology 2006, 42, 107-131
Shiroshita-Takeshita, A., Sakabe, M., Haugan, K., Hennan, J.K., and Nattel, S.: Model-dependent Effects of a Gap Junction Conduction Enhancing Antiarrhythmic Peptide (Rotigaptide) in Experimental Atrial Fibrillation.
Abstract for Heart Rhythm Society 27th Annual Scientific Sessions, May 17-20, 2006, Boston
Heart Rhytm, 2006, 3, No 5, May Supplement S96, Abstract AB46-4
Udata, C., Micalizzi, M., Katz, A., M Giorgio, Q. and Meng, X.:
Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Rotigaptide (ZP123) Administered Intravenously to Healthy Subjects.
Poster presentation at The 2006 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Baltimore, Maryland, USA. March 7-11, 2006.
Clin Pharmacol Ther, 2006, 79, P77, Abstract PIII-70
Udata, C., Micalizzi, M., Katz, A., Giorgio, Q.M., and Meng, X.:
Six-Day Continuous IV Infusion Study of the Safety, Tolerability, and PK of Ascending Doses of Rotagaptide (ZP123) in Healthy Subjects.
Poster presentation at The 2006 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Baltimore, Maryland, USA. March 7-11, 2006.
Clin Pharmacol Ther, 2006, 79, P50, Abstract PII-53
Udata, C., Parks, V., Patat, A., Fauchoux, N. and Meng, X.:
Absence of Drug Interaction Between Rotigaptide (ZP123) and Digoxin.
Poster presentation at The 2006 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Baltimore, Maryland, USA. March 7-11, 2006.
Clin Pharmacol Ther, 2006, 79, P25, Abstract PI-71
Nattel, S and Carlsson, L.
Innovative approaches to anti-arrhythmic drug therapy.
Nature Reviews Drug Discovery 2006, 5, 1034-1049
Petersen. Y.M., Clausen, T.S., Kjølbye, A., Ørskov, C., Petersen, J.S., Larsen, B.D., Holst, J.J. and Poulsen, S.S.:
ZP1848, a new high efficacy glucagon-like peptide 2 mimetic, prevents indomethacin-induced inflammation in the small intestine in rats.
Poster abstract for 14th United European Gastroenterology Week (UEGW 2006), 21-25 October 2006, Berlin, Germany. Poster MON-G-247
Gut, 2006, 55, Supplement No. V, A130
Petersen, Y. M., Jepsen, T., Thorkildsen, C., Larsen, B.D., Petersen, J.S. and Kjølbye, A.:
ZP 1846, a novel stable, high efficacy glucagon-like peptide 2 mimetic, stimulates small intestinal growth and prevents 5-fluorouracil-induced small intestinal injury in C57BL mice.
Abstract for 14th United European Gastroenterology Week (UEGW 2006), 21-25 October 2006, Berlin, Germany. Presentation OP-G-213
Gut, 2006, 55, Supplement No. V, A48
Haugan H., Miyamoto, T., Takeishi, Y., Kubota, I., Nakayama, J., Shimojo, H., and Hirose, M.:
Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria.
Basic Clin. Pharmacol. Toxicol. 2006, 99, 71-79
Guerra, J.M., Everett, T.H., Lee, K.W., Wilson, E. and Olgin, J.E.:
Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation.
Circulation 2006, 114, 110-118
Axelsen, L.N., Stahlhut, M., Mohammed, S., Larsen, B.D., Nielsen, M.S., Holstein-Rathlou, N.-H., Andersen, S., Jensen, O.N., Hennan, J.K. and Kjølbye, A.L.:
Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123).
Journal of Molecular and Cellular Cardiology, 2006, 40, 790–798
Calò, G.:
Therapeutic opportunities for nociceptin/orphanin FQ receptor ligands.
European Opioid Conference 2006, Salamanca, Spain, 19-21 April, 2006. Abstract S4
Petersen, J.S.:
ZP120 - introduction of a new `first-in-class' agent for the treatment of acute heart failure. European Opioid Conference 2006, Salamanca, Spain, 19-21 April, 2006. Abstract S4.2
Stahlhut, M., Petersen, J.S., Hennan, J.K. and Ramirez, M.T.:
The Antiarrhythmic Peptide Rotigaptide (ZP123) Increases Connexin 43 Protein Expression in Neonatal Rat Ventricular Cardiomyocytes
Cell Communication and Adhesion 2006, 13, 21–27
Hennan, J.K., Swillo, R.E., Morgan, G.A., Keith, J.C., Schaub, R.G., Smith, R.P., Feldman, H.S., Haugan, K., Kantrowitz, J., Wang, P.J., Abu-Qare, A., Butera, J., Larsen, B.D. and Crandall, D.L.:
Rotigaptide (ZP123) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs.
J Pharm Exp Ther, 2006, 317, 236–243
Clarke, T.C., Thomas, D., Petersen, J.S., Evans, W.H., and Martin, P.E.M.:
The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43.
Br. J. Pharmacol. 2006, 147, 486–495
Haugan, K., Marcussen, N., Kjølbye, A.L.; Nielsen, M.S.; Hennan, J.K. and Petersen, J.S.:
Treatment With The Gap Junction Modifier Rotigaptide (ZP123) Reduces Infarct Size In Rats With Chronic Myocardial Infarction.
J Cardiovasc Pharmacol, 2006, 47, 236–242
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.
Home Legal Disclaimer Updated: 1.9.2010